Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$101.14 USD
-2.01 (-1.95%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $101.28 +0.14 (0.14%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$101.14 USD
-2.01 (-1.95%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $101.28 +0.14 (0.14%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Small-Cap ETFs in Focus on Trade Woes, Solid Economic Data
by Zacks Equity Research
The small-cap space has been outperforming the large caps this year. Here are the most-popular small-cap ETFs.
Looking for a Top Momentum Pick? Why Ligand Pharmaceuticals (LGND) is a Great Choice
by Zacks Equity Research
Does Ligand Pharmaceuticals (LGND) have what it takes to be a top stock pick for momentum investors? Let's find out.
Top Ranked Momentum Stocks to Buy for September 7th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 7th:
bluebird (BLUE) Reports Updated Data on Lenti-D Gene Therapy
by Zacks Equity Research
bluebird bio (BLUE) announces updated results from phase II/III Starbeam study of its Lenti-D gene therapy in boys aged 17 years or below with CALD.
ProQR Up More Than 120% on Favorable Eye Disorder Study Data
by Zacks Equity Research
ProQR Therapeutics (PRQR) presents positive data from a phase I/II study on QR-110, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.
Top Ranked Momentum Stocks to Buy for September 6th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 6th:
Horizon Pharma Completes Enrollment in Eye Disease Study
by Zacks Equity Research
Horizon Pharma (HZNP) completes early enrollment for the confirmatory phase III study of teprotumumab, which is being evaluated for the treatment of thyroid eye disease.
Bayer (BAYRY) Misses on Q2 Earnings, Closes Monsanto Buyout
by Zacks Equity Research
Bayer (BAYRY) misses earnings estimates in the second quarter of 2018. The company completes the acquisition of Monsanto for $63 billion.
Ligand (LGND) Up 4.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (LGND) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for September 4th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 4th
Bayer's (BAYRY) Jivi Gets FDA Approval to Treat Hemophilia A
by Zacks Equity Research
Bayer's (BAYRY) Jivi gets FDA approval for the treatment of hemophilia A in previously-treated adults and adolescents aged 12 years and older.
Alnylam Gets European Nod for First-Ever RNAi Therapeutic
by Zacks Equity Research
Alnylam's (ALNY) Onpattro, the first ever RNA interference (RNAi) therapeutic, has been granted marketing authorization by the European Commission.
Vertex Inks Deal With Genomics to Make Serious Disease Drugs
by Zacks Equity Research
Vertex (VRTX) signs a three-year collaboration contract with Genomics to develop novel drug targets for advancing discovery of precision medicines.
Ultragenyx to File NDA for LC-FAOD Candidate on Existing Data
by Zacks Equity Research
Ultragenyx (RARE) plans to submit an NDA for UX007 for the treatment of LC-FAOD on existing data, as per agreement with the FDA.
Amgen's Leukemia Drug Blincyto Gets EU Nod for Pediatric Use
by Zacks Equity Research
Amgen's (AMGN) leukemia drug, Blincyto gets approval in EU for use in pediatric patients aged one year or older.
Ultragenyx's Rare Disease Drug Mepsevii Gets EU Approval
by Zacks Equity Research
Ultragenyx's (RARE) Mepsevii gets European approval for the treatment of Mucopolysaccharidosis VII.
Bayer's Blood Thinner Xarelto Fails in Line Extension Studies
by Zacks Equity Research
Bayer (BAYRY) and partner Johnson & Johnson's drug, Xarelto shows no significant difference when compared with placebo in two late-stage phase III studies.
5 Health Care ETFs Outperforming XLV on YTD Basis
by Zacks Equity Research
Health care ETFs provide handsome returns year to date.
Why Ligand (LGND) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Ligand (LGND).
Shire's Takhzyro Gets FDA Nod for Hereditary Angioedema
by Zacks Equity Research
Shire???s (SHPG) Takhzyro gets approval from the FDA for the treatment of hereditary angioedema in patients 12 years of age and older. It is the first-of-its-kind mAb preventive treatment for the same.
Alexion's BLA for ALXN1210 Gets Priority Review From FDA
by Zacks Equity Research
The FDA grants priority review to Alexion's (ALXN) BLA for its C5 complement inhibitor ALXN1210 with respect to the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA
by Zacks Equity Research
The FDA accepts Evoke Pharma's (EVOK) regulatory application seeking approval of its pipeline candidate, Gimoti, for treating diabetic gastroparesis. Shares up.
Zacks.com featured highlights include: Ligand, Energy Recovery, Turtle Beach, Cleveland-Cliffs and SVB
by Zacks Equity Research
Zacks.com featured highlights include: Ligand, Energy Recovery, Turtle Beach, Cleveland-Cliffs and SVB
Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (LGND) Outperforming Other Medical Stocks This Year?